Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05413915
Other study ID # QC-TFR1-ABL001
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 19, 2023
Est. completion date December 2025

Study information

Verified date October 2023
Source Sir Mortimer B. Davis - Jewish General Hospital
Contact Caroline Lambert, PhD
Phone 514-340-8222
Email clambert@jgh.mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to establish if consolidation of imatinib-treated patients in stable DMR through the addition of asciminib, can lead to superior rates of TFR1, compared to imatinib alone in Chronic Phase-Chronic Myelogenous Leukemia patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: In order to be eligible, candidates must fulfill all the following criteria: 1. Male or female patients aged at least 18 years of age with a confirmed diagnosis of CML-CP. 2. Written informed consent prior to any screening procedures 3. Available and willing to comply with all study assessments. 4. Imatinib treatment ongoing > 4 years, and currently receiving: - Standard dose 400 mg PO QD or; - 300 mg PO QD for at least 6 months (see below) 5. CML in deep molecular response (DMR, at least MR4 IS) for at least 12 months prior to randomization (documented through at least 3 PCRs test results over the period of 12 months prior to randomization, showing BCR-ABL1 levels = 0.01% IS (International Scale) and no result over >0.01%). For patients receiving 300 mg imatinib QD, minimum of two (2) of those qPCRs evaluations must have been obtained at least 3 months apart while on 300 mg imatinib. 6. ECOG performance status of 0-2. 7. Adequate organ function, defined by: - Absolute Neutrophil Count (ANC) = 1.5 x 10^9/L - Platelets = 75 x 10^9/L (without the requirement for transfusion for 14 days) - Hemoglobin = 90 g/L (without the requirement for transfusion for 14 days) - Serum creatinine < 132 µmol/L - Total bilirubin = 1.5 x ULN (except for patients with Gilbert's syndrome who may only be included with total bilirubin = 3.0 x ULN) - Aspartate transaminase (AST) = 3.0 x ULN - Alanine transaminase (ALT) = 3.0 x ULN - Alkaline phosphatase = 2.5 x ULN - Serum lipase = 1.5 x ULN 8. Serum levels of potassium, magnesium, total calcium within the normal laboratory range. Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed. - potassium increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance within normal limits (as estimated by the Cockcroft-Gault formula, appendix 1) - calcium increase to 3.1 mmol/L is acceptable if associated with creatinine clearance within normal limits - magnesium increase up to 1.23 mmol/L if associated with creatinine clearance within normal limits 9. No previous CML-AP/BP by MDACC criteria nor resistance to TKI by ELN criteria. 10. Never attempted TFR 11. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test before initiation of study treatment, and must also use highly effective methods of contraception to continue for at least 14 days after the last dose of study treatment, or for the duration of a monthly cycle of oral contraception, whichever is longer. Acceptable forms of highly effective contraception methods include: 1. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception 2. Male/female sterilization defined as: 1. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed and documented by follow up hormone level assessment 2. Male sterilization of the sole partner (at least 6 months prior to screening) of a female patient on the study. 3. A combination of any two of the following (i+ii or i+iii or ii+iii): i) Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository ii) Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception iii) Placement of an intrauterine device (IUD) or intrauterine system (IUS) Exclusion Criteria: 1. Patients known to be in second CP-CML after previous progression to AP/BC-CML 2. Previous treatment with a TKI other than imatinib. 3. Prior allogeneic transplant. 4. Tolerance concerns to continue imatinib on study, as determined by the investigator. 5. Treatment with strong inducers/inhibitors of CYP3A4. 6. Known atypical ABL1-BCR transcript that precludes use of IS system for monitoring. 7. Current or prior history of another malignancy within the past 2 years, unless it is a solid tumor with a life expectancy of at least 3 years and its treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (for example, patients who have undergone complete resection of an in situ carcinoma, or who have a low risk indolent prostate cancer are eligible). History or current diagnosis of cardiac disease indicating significant risk or safety for subjects participating in the study such as: 1. History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization 2. Concomitant clinically significant arrhythmias 3. Resting QTcF = 450 msec (male) or = 460 msec (female) prior to randomization 4. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: i. Risk factors for Torsades de Pointes ii. Concomitant medications with a "known" risk of Torsades de Pointes iii. inability to accurately determine the QTcF interval, unless this is due to the presence of a pacemaker. 8. History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease 9. Patients who have undergone major surgery =2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 10. Subjects with other severe or uncontrolled medical conditions that in the opinion of the investigator may compromise their compliance with the protocol or may represent an unacceptable risk to their safety (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase). 11. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1. 12. Known allergy or hypersensitivity to asciminib or any of its excipients. 13. Patients who are pregnant or breastfeeding or WOCBP not employing an effective method of birth control. 14. Known infection with Human Immunodeficiency virus (HIV), chronic Hepatitis B (HBV) or chronic hepatitis C infection (HCV). Hepatitis B and C testing will be performed at screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Asciminib
Tyrosine kinase inhibitor
Imatinib
Tyrosine kinase inhibitor

Locations

Country Name City State
Canada Clinical Research Unit - Jewish General Hospital Montreal Quebec
Canada Hôpital Maisonneuve-Rosemont (CIUSSS EMTL) Montréal Quebec
Canada Hôpital Enfant-Jésus - CHUQ Québec
Canada Hôpital Fleurimont - CHUS (CIUSSS Estrie) Sherbrooke Quebec

Sponsors (2)

Lead Sponsor Collaborator
Sarit Assouline Novartis

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival rate Occurrence of death or loss of deep molecular response (DMR, MR4 (4-log reduction in BCR-ABL1 or better)) or loss of major molecular response (MMR, MR3 (3-log reduction in BCR-ABL1)) at any time. randomization until 12 months after discontinuation of all TKI among randomized patients
Secondary Event-free survival rate Occurrence of death or "molecular relapse" as defined as any loss of MR4 status during the Consolidation period OR any loss of MR3 by qPCR at any time randomization to 6 months after discontinuation of TKI among all randomized patients
Secondary Time to molecular relapse Time in months to loss of MR3 among subjects who attempt treatment-free remission (TFR) Tyrosine kinase inhibitor (TKI) discontinuation until loss of MR3 (up to 1 year)
Secondary Molecular relapse free rate Sustained MR3 status at 12 months among patients who attempt TFR TKI discontinuation until loss of MR3 (up to 1 year)
Secondary Cumulative incidence of adverse events grade = 3 in each arm, using CTCAE 5.0 Safety and tolerability of asciminib when used with imatinib from first dose/randomization until 30 days post last dose
Secondary Association between duration of prior imatinib exposure and TFR (Treatment Free Remission) as assessed by Hazard Ratio from randomization until up to 12 months post consolidation
Secondary Association between duration of deep molecular response (DMR) and TFR (Treatment Free Remission) as assessed by Hazard Ratio from randomization until up to 12 months post consolidation
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT02057185 - Occupational Status and Hematological Disease
Recruiting NCT03326310 - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Phase 1
Recruiting NCT04621851 - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed NCT01207440 - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Active, not recruiting NCT02917720 - 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients Phase 2
Not yet recruiting NCT02883036 - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia N/A
Withdrawn NCT01188889 - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Phase 1/Phase 2
Completed NCT01795716 - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body Phase 1
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Approved for marketing NCT00905593 - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Phase 3
Terminated NCT00573378 - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Phase 2
Completed NCT00469014 - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT00257647 - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) N/A
Completed NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT Phase 3
Completed NCT06148493 - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed NCT00375219 - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Phase 2